>MNTA – If the FDA has nixed two other generic Lovenox approvals, why should Momenta's be any different?<
As of three days ago, both of those other ANDA’s were presumably still open. What their status is now is unclear; however, if they have been rejected, that’s a good thing, not a bad thing, for MNTA.
Why? Because the economic terms of MNTA’s Lovenox collaboration with Sandoz are more favorable for MNTA if the Teva and Amphastar ANDA’s fail.
>Isn't the FDA just continuing its established pattern of shooting down attempts at a generic Lovenox?<
Where is there a pattern? The first FDA action on any of these ANDA’s was presumably just three days ago.
Market Data 
Markets 
AI
